FDA Clearance Tracker · P170011-S011
Impella RP
Last checked: Nov 20, 2026Latest source record: May 21, 2019 (this decision)Source: openFDAMethods & limitations
Decided
May 21, 2019
Approved
Time to decision
67 days
Received Mar 15, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P170011-S011
- Device name
- Impella RP
- Applicant
- Abiomed, Inc.
- Applicant location
- Danvers, MA
- Received
- Mar 15, 2019
- Decided
- May 21, 2019
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P170011
Device type
- Device class
- Class III
- Regulation
- 21 CFR 870.4360
- Specialty
- Cardiology
FDA's approval statement
As written in FDA's record.
Approval of the revised protocol for the Impella RP-RWE Eval and Reporting post-approval study protocol.
Source documents
Other decisions for Abiomed, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K252766 · Decided Oct 8, 2025 · 40 days after receipt
Device type: Introducer, Catheter (DYB) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.